This litigation has concluded and we are proud to report that our clients' claims have been successfully resolved. The amounts of all individual client recoveries are confidential, both by settlement agreement and by attorney-client privilege. MLG is no longer accepting cases involving this product.
Published on Saturday, July 25, 2015 by Staff
The U.S. Food and Drug Administration has issued a Warning Letter to C. R. Bard and its subsidiary Bard Peripheral Vascular, Inc. on July 23rd, 2015. The FDA alleges that Bard's "Recovery Cone Retrieval System" is being marketed and sold without approval and clearance from the FDA to do so. The Warning Letter further alleges that the "Recovery Cone Retrieval System" is misbranded in that C.R. Bard did not notify the FDA that it intended to market and sell the System in the U.S.
The FDA has requested that C.R. Bard halt the marketing and sale of the "Recovery Cone Retrieval System" as continuing to do so is unauthorized and in violation of FDA's Regulations and federal law.
This litigation has concluded and we are proud to report that our clients' claims have been successfully resolved. The amounts of all individual client recoveries are confidential, both by settlement agreement and by attorney-client privilege. MLG is no longer accepting cases involving this product.